Unexplained Variations in Patient Admissions: Part II

For my last article, I wrote about unexplained clinical variation as it pertains to surgical procedures. Today I continue exploring this theme.

For men with low-risk prostate cancer, randomized controlled trials have found that active treatment such as radiation or prostatectomy does not improve mortality rates as compared to an initial approach of observation. Thus, evidence-based guidelines conclude that observation is a reasonable initial strategy.

An analysis of a national database by Tyson and colleagues published this year included over 20,000 men over 66 years of age with low-risk prostate cancer and their nearly 1,900 treating urologists. Wide variation in the utilization of observation as a treatment strategy was found. Some urologists employed observation 5 to 30 percent of the time, while others used it as often as 60 to 70 percent of the time.

Considering the significant adverse effects of active treatment, such as impotence and urinary incontinence, and the lack of demonstrated mortality benefit of active treatment in low-risk patients, this degree of variation is concerning, from a cost perspective as well as a patient safety perspective.

Another area in which we can assess unexplained clinical variation is treatment of carotid artery stenosis.

When symptomatic, as stroke or transient ischemic attack (TIA), revascularization can be beneficial in terms of ensuring reduced subsequent incidence of stroke. When a patient is asymptomatic (that is, no history of stroke or TIA), treatment of carotid artery stenosis is more controversial. Evidence-based guidelines suggest that for asymptomatic patients, revascularization only should be considered in the presence of at least 70 percent stenosis, and even in this group, whether the procedure is beneficial or harmful is a close call.

With this as background, examination of the results of a study published this year by Shean and colleagues is relevant. They examined a database of over 57,000 carotid revascularization procedures, 85 percent carotid endarterectomy and 15 percent carotid artery stenting. For endarterectomy, the percentage of treated patients who were asymptomatic varied across regions from 46 to 69 percent, and for stenting from 29 to 51 percent.

Limiting the analysis to asymptomatic patients with stenosis of less than 70 percent, for whom revascularization is not of clear benefit, we find variation, but also disturbingly high utilization rates. The proportion of endarterectomies that were performed on this group varied threefold, from 3 to 9 percent, and for carotid stenting it varied more than sevenfold, from 3 percent to a stunning 22 percent.

Beyond the observed variation, it is difficult to account for a significant number of procedures being performed on patients for whom the risks almost certainly outweigh the potential benefits.

It is this sort of variation and questionable utilization that makes use of evidence-based guidelines so necessary. The twin concerns regarding cost and patient safety demand attention. At the same time, it is only through use of guidelines that are evidence-based and clinically valid that we can safely and appropriately intervene.

Substituting arbitrary criteria or target utilization rates is neither appropriate nor beneficial to patients. It is through the application of guidelines that are clinically sound and evidence-based, such as those produced by MCG, that we can address both the cost and the safety aspects of unexplained clinical variation.

Links to cited studies:

Shean KE, et al. Regional variation in patient selection and treatment for carotid artery disease in the Vascular Quality Initiative. Journal of Vascular Surgery 2017;66(1):112-121. DOI: 10.1016/j.jvs.2017.01.023.

Tyson MD, et al. Urologist-level correlation in the use of observation for low- and high-risk prostate cancer. JAMA Surgery 2017;152(1):27-34. DOI: 10.1001/jamasurg.2016.2907.

Facebook
Twitter
LinkedIn

Bill Rifkin MD, FHM, FACP

Dr. Bill Rifkin is the associate vice president and managing editor of MCG Health. Dr. Rifkin oversees all research and content published by MCG Health that is focused on acute inpatient care. His expertise expands to hospital medicine and clinical care, where he has published multiple research documents.

Related Stories

Leave a Reply

Please log in to your account to comment on this article.

Featured Webcasts

2026 IPPS Masterclass 3: Master MS-DRG Shifts and NTAPs

2026 IPPS Masterclass Day 3: MS-DRG Shifts and NTAPs

This third session in our 2026 IPPS Masterclass will feature a review of FY26 changes to the MS-DRG methodology and new technology add-on payments (NTAPs), presented by nationally recognized ICD-10 coding expert Christine Geiger, MA, RHIA, CCS, CRC, with bonus insights and analysis from Dr. James Kennedy.

August 14, 2025
2026 IPPS Masterclass Day 2: Master ICD-10-PCS Changes

2026 IPPS Masterclass Day 2: Master ICD-10-PCS Changes

This second session in our 2026 IPPS Masterclass will feature a review the FY26 changes to ICD-10-PCS codes. This information will be presented by nationally recognized ICD-10 coding expert Christine Geiger, MA, RHIA, CCS, CRC, with bonus insights and analysis from Dr. James Kennedy.

August 13, 2025
2026 IPPS Masterclass 1: Master ICD-10-CM Changes

2026 IPPS Masterclass Day 1: Master ICD-10-CM Changes

This first session in our 2026 IPPS Masterclass will feature an in-depth explanation of FY26 changes to ICD-10-CM codes and guidelines, CCs/MCCs, and revisions to the MCE, presented by presented by nationally recognized ICD-10 coding expert Christine Geiger, MA, RHIA, CCS, CRC, with bonus insights and analysis from Dr. James Kennedy.

August 12, 2025

Trending News

Featured Webcasts

The Two-Midnight Rule: New Challenges, Proven Strategies

The Two-Midnight Rule: New Challenges, Proven Strategies

RACmonitor is proud to welcome back Dr. Ronald Hirsch, one of his most requested webcasts. In this highly anticipated session, Dr. Hirsch will break down the complex Two Midnight Rule Medicare regulations, translating them into clear, actionable guidance. He’ll walk you through the basics of the rule, offer expert interpretation, and apply the rule to real-world clinical scenarios—so you leave with greater clarity, confidence, and the tools to ensure compliance.

June 19, 2025
Open Door Forum Webcast Series

Open Door Forum Webcast Series

Bring your questions and join the conversation during this open forum series, live every Wednesday at 10 a.m. EST from June 11–July 30. Hosted by Chuck Buck, these fast-paced 30-minute sessions connect you directly with top healthcare experts tackling today’s most urgent compliance and policy issues.

June 11, 2025
Open Door Forum: The Changing Face of Addiction: Coding, Compliance & Care

Open Door Forum: The Changing Face of Addiction: Coding, Compliance & Care

Substance abuse is everywhere. It’s a complicated diagnosis with wide-ranging implications well beyond acute care. The face of addiction continues to change so it’s important to remember not just the addict but the spectrum of extended victims and the other social determinants and legal ramifications. Join John K. Hall, MD, JD, MBA, FCLM, FRCPC, for a critical Q&A on navigating substance abuse in 2025.  Register today and be a part of the conversation!

July 16, 2025

Trending News

Prepare for the 2025 CMS IPPS Final Rule with ICD10monitor’s IPPSPalooza! Click HERE to learn more

Get 15% OFF on all educational webcasts at ICD10monitor with code JULYFOURTH24 until July 4, 2024—start learning today!

CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 2 with code CYBER24